A number of studies have demonstrated that the vascular endothelial growth factor (VEGF), a potent mitogen for endothelial cells, plays a principal role in the development of neovascularization in various chorioretinal diseases.7,8 There have been recent reports on the use of intravitreal bevacizumab (IVB), a pan anti-VEGF antibody, for CNV secondary to high myopia,9–20 angioid streaks,21,22 CSC,23 idiopathic,23,24 OHS,25,26 and choroidal osteoma.27 However, limited information is available on the long-term effect of treatment with VEGF-blocking agents on CNV secondary to non-AMD causes. Here, VEGFA is linked to angioid streaks.